# Remigen targets $150m fund with corporate backing

By Robert Lavine · 2014-07-28

Source: https://globalventuring.com/blog/2014/07/28/remigen-targets-150m-fund-with-corporate-backing/
Updated: 2018-09-25
Publisher: Global Venturing (Global Corporate Venturing / GCV)

> Sumitomo Dainippon and Taiho Pharmaceutical have each invested $30m in the firm, which will target early stage pharmaceutical companies.

Two Japan-based pharmaceutical companies have each committed $30m to a new venture capital firm, Remiges Ventures, which will target early stage drug developers.

 Sumitomo Dainippon Pharma and Taiho Pharmaceutical, which operates as a subsidiary of Otsuka Holdings, are backing the firm, which has offices in Massachusetts and Tokyo, they stated in separate press releases last week.

 Remiges has so far raised $70m of a targeted $150m for its inaugural fund, Remiges BioPharma Fund, according to an SEC filing.

 The fund will concentrate on companies working on drugs to treat underserved medical conditions where there is a clear path to regulatory approval and definable commercial opportunity in the United States.

 Taro Inaba, who previously spent 11 years at Mitsui Ventures, a corporate venturing subsidiary of diversified corporation Mitsui, including a stint as its chief executive, is Remiges’ managing director. Walter Olesiak, who worked at Mitsui Ventures for eight years, is a partner at the firm.


Citation file: https://globalventuring.com/llms.txt
